BiotechTube

Methylprednisolone + Prednisolone + Sirolimus

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-Linked Myotubular Myopathy

Conditions

X-Linked Myotubular Myopathy

Trial Timeline

Dec 15, 2025 → Oct 31, 2027

NCT ID
NCT07052929

About Methylprednisolone + Prednisolone + Sirolimus

Methylprednisolone + Prednisolone + Sirolimus is a phase 1/2 stage product being developed by Astellas Pharma for X-Linked Myotubular Myopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07052929. Target conditions include X-Linked Myotubular Myopathy.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07052929Phase 1/2Recruiting

Competing Products

20 competing products in X-Linked Myotubular Myopathy

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
28
BurosumabKyowa KirinPhase 1/2
41
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1/2
41
KRN23Kyowa KirinPhase 3
77
burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinApproved
85
burosumabKyowa KirinPhase 2
52
BurosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 1/2
41
Placebo + KRN23Kyowa KirinPhase 1
33
BurosumabKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1
33
KRN23Kyowa KirinApproved
85
KK8123Kyowa KirinPhase 1/2
41

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85